Hauj lwm lawm

Kev tsis

Vim li cas thiaj xaiv peb?

Kev daws teeb meem ib zaug

Kev paub nplua nuj

Fengfu Pharma, headquartered nyob rau hauv Hangzhou, Tuam Tshoj, nrog 3 ntau lawm bases nyob rau hauv Shandong, Zhejiang thiab Hebei nyias, uas muaj ntau xyoo ntawm kev paub nyob rau hauv zus tau tej cov APIs, vitamins thiab tshuaj cov khoom. Cov chaw no tau lees paub GMP, ISO, FAMI-QS, KOSHER, HALAL, thiab lwm yam.

Siab zoo

Peb tau ua tiav kev tswj hwm peb cov khoom tsim, tsim, thiab tsim cov txheej txheem, ua tsaug rau peb cov cuab yeej siv siab heev, cov txheej txheem, thiab cov chaw soj ntsuam.

Kev pabcuam zoo

Peb lub hom phiaj yog los muab koj cov khoom lag luam zoo thiab cov kev pabcuam tshaj lij rau kev sib nrig sib pab. Peb kuj txaus siab ua haujlwm nrog cov neeg koom tes thoob ntiaj teb los tsim kom muaj lub neej yav tom ntej zoo ua ke.

Upadacitinib CAS yog dab tsi 1310726-60-3

Upadacitinib yog tshuaj siv rau kev kho mob rheumatoid mob caj dab, psoriatic mob caj dab, atopic dermatitis, ulcerative colitis, Crohn tus kab mob, ankylosing spondylitis, thiab axial spondyloarthritis.Upadacitinib yog ib tug Janus kinase (JAK) inhibitor uas ua hauj lwm los ntawm Janus kinase (JAK) enzyme inhibitor uas ua haujlwm los ntawm Janus kinase (JAK) inhibitor. kinases.Cov enzymes no koom nrog hauv kev teeb tsa cov txheej txheem uas ua rau o, thiab thaiv lawv cov nyhuv coj o nyob rau hauv cov pob qij txha tswj.

Upadacitinib CAS 1310726-60-3

Khoom: Upadacitinib CAS 1310726-60-3
Lwm Lub Npe: Upadacitinib; ABT-494; ABT-494 (Upadacitinib) dawb puag; ABT-494 (Upadacitinib);
Lub npe tshuaj: (3S,4R)-3-Ethyl-4-(3H-imidazo[1,{7}}a]pyrrolo[2,3-e]pyrazin{10}} yl)-N-(2,2,2-trifluoroethyl)-1-pyrrolidinecarboxamide
Cov mis mos molecular: C17H19F3N6O

Ruxolitinib CAS 941678-49-5

Khoom: Ruxolitinib CAS 941678-49-5
Lwm Lub Npe: INCB018424; Ruxolitinib; Ruxolitinib Phosphate API; Ruxolitinib API; Ruxolitinib Intermediates;
Lub npe tshuaj: (3R)-3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1 H-pyrazol{11}}yl]propanenitrile
Cov mis mos molecular: 306.37
Molecular hnyav: C17H18N6

Tadalafil CAS 171596-29-5

Khoom: Tadalafil CAS 171596-29-5
Lwm Lub Npe: Tadalafil API; Cialis Tadalafil API; Adcirca API; CAS 171596-29-5; 171596-29-5; IC 351; ICOS 351; Cialis 98%; Tildenafil; UK 336017;
Lub npe tshuaj: (6R,12aR)-6-(1,3-Benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro{{13} }methylpyrazino[1',2':1,6]pyrido[3,{19}}b]indole-1,4-dione
Cov mis mos molecular: C22H19N3O4
Molecular hnyav: 389.41

Lidocaine Hydrochloride CAS TSIS TAU

Khoom: Lidocaine hydrochloride CAS 6108-05-0
Lwm Lub Npe: Lidocaine Hydrochloride Monohydrate; Lidocaine hydrochloride anhydrous; Lidocaine; Lidocaine HCl; Lignocaine Hydrochloride; Lignocaine HCl; 6108-05-0; 137-58-6;
Lub npe tshuaj: 2-Dimethylamino-N-(2,6-dimethylphenyl)acetamide hydrochloride
Cov mis mos molecular: C14H25ClN2O2
Molecular hnyav: 288.814

Ropivacaine Hydrochloride CAS 132112-35-7

Khoom: Ropivacaine hydrochloride CAS 132112-35-7
Lwm Lub Npe: Ropivacaine HCl; Ropivacaine Hydrochloride Monohydrate; Naropin API; Ropivacaine Monohydrochloride; 132112-35-7;
Cov mis mos molecular: C17H26N2O.ClH.H2O
Molecular hnyav: 328.88
CAS Nr.: 132112-35-7

Prilocaine Hydrochloride CAS 1000000000

Khoom: Prilocaine hydrochloride CAS 1786-81-8
Lwm Lub Npe: Prilocaine Hydrochloride; Prilocaine; Prilocaine HCl; Citanest API; Prilocaine Monohydrochloride; 721-50-6; 1786-81-8;
Lub npe tshuaj: 2-(Propylamino)-o-propionotoluidide hydrochloride;
Cov mis mos molecular: C13H21ClN2O

Pramoxine Hydrochloride CAS 10000-00-1

Khoom siv: Pramoxine hydrochloride CAS 637-58-1
Lwm Lub Npe: Pramoxine HCL API; Pramoxine Hydrochloride 637-58-1; Pramoxine Hydrochloride (1554002); Pumocaine hydrochloride; Plamoxine hydrochloride; Pramoxine Monohydrochloride; Pramoxine Hydrochloride Monohydrate; 637-58-1;

Bupivacaine Hydrochloride CAS TSIS TAU

Khoom: Bupivacaine Hydrochloride CAS 73360-54-0
Lwm Lub Npe: Bupivacaine HCl hydrate; bupivacaine hydrochloride hydrate; Bupivacaine; 2180-92-9; Bupivacaine HCl; Bupivacaine Hydrochloride Monohydrate; Marcaine; Sensorcaine; Bupivacaine Monohydrochloride;

Articaine Hydrochloride CAS TSIS TAU

Khoom: Articaine hydrochloride CAS 23964-57-0
Lwm Lub Npe: Articaine HCl; Carticaine hydrochloride; Septocaine; Articaine Hydrochloride Monohydrate; Septocaine; 23964-57-0;
Lub npe tshuaj: 4-methyl-3-[[(1-oxo-2-(propylamino)propyl)amino]methyl]benzoic acid hydrochloride

Leej twg tuaj yeem noj Upadacitinib CAS 1310726-60-3

Updacacitinib tuaj yeem raug sau los ntawm tus kws kho mob rheumatologist rau cov neeg laus uas muaj mob rheumatoid mob caj dab nruab nrab lossis hnyav. Nws kuj tseem siv tau los kho mob caj dab psoriatic.
Upadacitinib yuav tsis pib yog tias:
● Koj tus mob tsis ua haujlwm
● Koj tsis tau sim lwm yam kev kho mob rau koj tus mob ua ntej
● Koj muaj kab mob
Ua ntej koj tau txais cov tshuaj upadacitinib, cov kws kho mob yuav siv cov qhab nia ntsuas seb koj cov pob qij txha mob los yog o thiab koj xav li cas. Qhov no pab lawv ua haujlwm kom paub tias koj mob caj dab ua haujlwm li cas. Koj tseem yuav tau kuaj ntshav ua ntej kev kho mob pib saib seb cov tshuaj puas haum rau koj.
Koj tus kws kho mob yuav tau kuaj seb koj puas tau kis tus kab mob ntsws (TB). Txawm hais tias koj tsis muaj tsos mob, cov kab mob uas ua rau TB tseem tuaj yeem muaj nyob hauv lub cev, thiab koj yuav xav tau kev kho mob los daws qhov no ua ntej pib upadacitinib.
Yog tias koj tau muaj kab mob siab rau koj yuav xav tau kev kuaj xyuas tsis tu ncua rau qhov no vim tias upadacitinib tuaj yeem ua rau muaj kev pheej hmoo ntawm kab mob siab rov qab los.
Upadacitinib feem ntau yog sau nrog methotrexate tshwj tsis yog tias muaj laj thawj vim li cas koj tsis tuaj yeem noj methotrexate. Txawm li cas los xij, upadacitinib yuav tsum tsis txhob siv nrog rau lwm yam tshuaj tiv thaiv kab mob lossis tshuaj lom neeg lossis lwm yam JAK inhibitors.
Upadacitinib tsis pom zoo yog tias koj cev xeeb tub, npaj cev xeeb tub lossis pub niam mis.
Koj tus kws kho mob yuav txiav txim siab tsis muab tshuaj upadacitinib yog tias koj tau muaj lossis muaj ib yam hauv qab no:
● Cov kab mob
● Kab mob ntawm lub ntsws, daim siab lossis lub raum
● Teeb meem plawv, ntshav siab, roj cholesterol siab, lossis ntshav txhaws (cov hlab ntsha sib sib zog nqus los yog pulmonary embolism)
● Kab mob plab
● Cancer

Indications rau Upadacitinib CAS 1310726-60-3

Upadacitinib CAS 1310726-60-3 yog ib tug tshiab FDA-pom zoo thib ob-kab tus neeg saib xyuas rau kev kho mob nruab nrab mus rau hnyav rheumatoid mob caj dab (RA) nyob rau hauv cov neeg mob uas tsis tau qhia ib tug txaus cov lus teb los yog intolerance rau thawj kab, methotrexate. yog ib tiam thib ob xaiv Janus kinase (JAK) inhibitor tsom rau JAK1 enzyme.
Kev siv upadacitinib nrog rau lwm yam JAK inhibitors (JAKinibs) lossis cov tshuaj tiv thaiv kab mob zoo li azathioprine thiab cyclosporine tsis raug qhia. Txawm li cas los xij, nws siv ua ke nrog cov kab mob uas tsis yog biologic hloov kho cov tshuaj tiv thaiv kab mob (DMARDs) xws li methotrexate tau txais kev txhawb nqa, thaum nws siv nrog cov tshuaj lom DMARDs tsis pom zoo. Thaum ua ke nrog thawj kab kev kho mob methotrexate, upadacitinib tiv thaiv kab mob kev loj hlob ntawm cov duab hluav taws xob thiab tswj kev kho mob zoo.
Kev kho mob rau cov neeg ua hauj lwm siv nyob rau hauv lwm yam kab mob autoimmune, xws li psoriatic mob caj dab (PA), atopic dermatitis (AD), ankylosing spondylitis (AS), giant cell arteritis (GCA), systemic lupus erythematosus (SLE), thiab inflammatory plob tsis so tswj kab mob (IBD. ), Crohn kab mob (CD) thiab ulcerative colitis (UC), tau pom cov txiaj ntsig tau txais txiaj ntsig.Upadacitinib yog qhov tseem ceeb tshaj plaws raws li thawj cov tshuaj noj qhov ncauj pom zoo los ntawm FDA los kho tus kab mob Crohn nruab nrab.
Upadacitinib yog FDA pom zoo rau cov neeg mob AD uas ua tsis tau lwm yam kev kho mob, suav nrog biologics, lossis thaum siv cov kev kho mob tsis pom zoo. Rau cov neeg mob ulcerative colitis (UC) uas muaj cov pouchitis rov tshwm sim tom qab ileal pouch-anal anastomosis (IPAA), American Gastroenterological Association (AGA) qhia txog kev kho cov tshuaj tiv thaiv kab mob zoo li upadacitinib. Upadacitinib tuaj yeem raug txiav txim siab rau cov tshuaj tua kab mob ntev-nyob ntawm pouchitis. Kev ntsuam xyuas endoscopic yog qhia kom paub meej tias qhov mob thiab txiav tawm lwm yam ua rau.
Rau cov neeg mob ulcerative colitis (UC) uas tau dhau IPAA thiab tsim cov tsos mob vim mob cuffitis, AGA qhia siv cov tshuaj pleev ib ce pom zoo rau UC kev kho mob, xws li tshuaj pleev mesalamine thiab tshuaj pleev corticosteroids. Upadacitinib lossis lwm yam tshuaj tiv thaiv kab mob tuaj yeem raug txiav txim siab rau cov mob refractory.

Thaum twg Kuv tuaj yeem cia siab tias Upadacitinib CAS 1310726-60-3 ua haujlwm

Upadacitinib ua haujlwm rau cov neeg mob feem ntau, feem ntau sai tom qab pib cov tshuaj. Qee tus neeg mob yuav hnov qhov kev txhim kho ntawm cov tsos mob sai li sai tau thaum 1-2 lub lis piam pib upadacitinib. Qee tus neeg mob yuav tsum muab sijhawm rau cov tshuaj pib ua haujlwm. Feem ntau, mus txog 2 lub hlis yuav tsum pom muaj txiaj ntsig. Yog tias tus neeg mob tsis pom qhov kev txhim kho tom qab noj cov tshuaj rau 2 lub hlis, qhov yuav ua rau nws ua haujlwm rau lawv txhua tus yog tsawg.

Upadacitinib CAS 1310726-60-3 Ua haujlwm li cas

Qhov mob ntawm atopic dermatitis (AD) yog tshwm sim los ntawm ib feem ntawm lub cev tiv thaiv kab mob hu ua cytokines uas tau nce hauv cov ntshav thiab ntawm daim tawv nqaij. Ob peb ntawm cov cytokines inflammatory siv lawv cov teebmeem los ntawm ib tug tshuaj teeb liab txoj hauv kev hlwb hu ua JAK-STAT txoj kev (Janus Kinase-Signal transducer thiab activators ntawm transcription).
JAK tsev neeg muaj plaub tus tswv cuab - JAK inhibitors tuaj yeem tsom ib lossis ntau dua ntawm cov neeg hauv tsev neeg no los thaiv cov kab mob tiv thaiv kab mob no thiab inhibit qhov mob ntawm cov cytokines tseem ceeb hauv AD.
Upadacitinib ua haujlwm los ntawm kev xaiv thaiv JAK1, uas yog ib tus neeg hauv tsev neeg JAK cuam tshuam nrog ntau yam cytokines thiab lwm txoj hauv kev uas ua rau mob thiab khaus hauv AD.

Yuav Siv Li Cas Upadacitinib CAS 1310726-60-3

Upadacitinib yog ib ntsiav tshuaj uas tau noj ib zaug ib hnub. Noj upadacitinib nrog zaub mov tuaj yeem txo qhov xeev siab lossis lwm yam kev mob plab uas koj xav tau. Upadacitinib tuaj yeem siv ib leeg lossis ua ke nrog methotrexate lossis lwm yam kab mob hloov kho cov tshuaj tiv thaiv kab mob (cDMARDs). Upadacitinib yuav tsum tsis txhob muab nrog rau lwm cov tshuaj biologic lossis lwm yam tshuaj uas txo koj lub cev tiv thaiv kab mob. Qee cov neeg mob yuav pib pom kev txhim kho nyob rau ob peb lub lis piam, tab sis nws yuav siv sij hawm ntau lub hlis kom tau txais txiaj ntsig tag nrho.

Hom kab mob dab tsi yog Upadacitinib siv rau

Upadacitinib yog ib qho DMARD siv los kho cov mob caj dab, xws li mob caj dab rheumatoid (RA).
Upadacitinib raug pom zoo rau kev siv ua ke nrog methotrexate (MTX) hauv cov neeg mob laus uas muaj mob nruab nrab mus rau hnyav RA uas tau teb tsis txaus rau MTX. Rau cov neeg mob uas tsis tuaj yeem zam MTX, upadacitinib tuaj yeem muab ua monotherapy.
Upadacitinib yeej tsis siv ua ke nrog cov tshuaj biologic. Kev sib txuas ntawm upadacitinib nrog kev kho mob biologic tsis pom zoo vim tias muaj kev pheej hmoo ntau ntxiv rau kev kis kab mob.

Cov txiaj ntsig dab tsi ntawm Upadacitinib CAS 1310726-60-3 Tau Qhia hauv Kev Kawm

Rheumatoid mob caj dab
Tsib txoj kev tshawb fawb suav nrog tag nrho ze li ntawm 4,400 tus neeg mob pom tias upadacitinib muaj txiaj ntsig zoo los txo cov tsos mob ntawm cov neeg mob uas muaj mob rheumatoid mob caj dab. Cov kev tshawb fawb no suav nrog kev ntsuas kab mob hauv 28 pob qij txha hauv lub cev ntawm tus qauv ntsuas. Lawv tau pom tias upadacitinib muaj txiaj ntsig zoo ntawm kev tshem tawm cov tsos mob lossis ua tiav cov kab mob qis hauv 43 txog 48% ntawm cov neeg mob; qhov no piv nrog cov kab mob txo qis hauv 14 mus rau 19% ntawm cov neeg mob muab cov placebo (kev kho dummy) lossis methotrexate.

Psoriatic mob caj dab
Ob txoj kev tshawb fawb uas muaj ntau dua 2,000 cov neeg mob uas muaj mob psoriatic mob caj dab txawm hais tias kev kho mob ua ntej pom tias upadacitinib, siv los ntawm nws tus kheej lossis nrog methotrexate, tau zoo dua li adalimumab (lwm cov tshuaj siv rau kev mob caj dab psoriatic) lossis placebo ntawm kev txo cov tsos mob ntawm tus kab mob. Nyob nruab nrab ntawm 57 thiab 71% ntawm cov neeg mob ntawm upadacitinib ntawm koob tshuaj 15 mg ib hnub twg tau txo qis cov tsos mob tom qab 12 lub lis piam ntawm kev kho mob, piv nrog 65% ntawm cov neeg mob kho nrog adalimumab thiab 24 txog 36% ntawm cov neeg mob ntawm cov placebo.

Axial spondyloarthritis
Rau ankylosing spondylitis ib 14- txoj kev tshawb fawb lub lim tiam uas muaj 187 tus neeg mob uas nws tus kab mob tsis tuaj yeem tswj tau zoo txaus nrog lwm cov kev kho mob tau pom tias upadacitinib tau zoo txo cov tsos mob ntawm tus kab mob. Ntawm cov neeg mob uas tau txais upadacitinib, nyob ib ncig ntawm 52% tau txo tus naj npawb thiab cov tsos mob hnyav, piv nrog 26% ntawm cov neeg mob ntawm cov placebo.
Tsis tas li ntawd, ib txoj kev tshawb fawb uas muaj nyob ib ncig ntawm 300 cov neeg mob uas tsis yog-radiographic axial spondyloarthritis uas nws cov kab mob tsis tuaj yeem tswj tau zoo txaus nrog lwm cov kev kho mob pom tau tias upadacitinib txhim kho cov tsos mob ntawm tus kab mob: cov tsos mob zoo dua li 40% tom qab 14 lub lis piam hauv 45% ntawm cov neeg mob. noj upadacitinib piv nrog 23% ntawm cov neeg mob ntawm cov placebo.

Atopic dermatitis
Upadacitinib tau ua haujlwm zoo ntawm kev tshem tawm ntawm daim tawv nqaij thiab txo cov kab mob thiab qhov hnyav ntawm cov neeg mob uas muaj mob atopic dermatitis nyob rau hauv peb qhov kev tshawb fawb tseem ceeb uas muaj tag nrho ntawm 2,584 tus neeg laus thiab menyuam yaus hnub nyoog 12 xyoos. Cov kev tshawb fawb piv cov teebmeem ntawm ob koob tshuaj upadacitinib (15 thiab 30 mg ib hnub), siv nrog lossis tsis muaj corticosteroids siv rau ntawm daim tawv nqaij, nrog cov placebo.
Kev kho mob nrog upadacitinib ntawm nws tus kheej ua rau txo qis thiab qhov hnyav ntawm tus kab mob hauv 60 txog 70% ntawm cov neeg mob noj 15 mg koob tshuaj thiab hauv 73 txog 80% ntawm cov neeg noj 30 mg, piv nrog 13 txog 16% ntawm cov neeg mob muab cov placebo. Cov tawv nqaij ntshiab lossis yuav luag ntshiab tau tiav hauv 39 txog 62% ntawm cov neeg mob noj upadacitinib, piv nrog 5 mus rau 8% ntawm cov neeg mob ntawm cov placebo.
Cov txiaj ntsig zoo sib xws tau pom thaum siv upadacitinib nrog corticosteroids: qhov twg thiab qhov hnyav ntawm tus kab mob tau txo qis hauv 65 mus rau 77% ntawm cov neeg mob noj upadacitinib piv rau 26% ntawm cov neeg mob ntawm cov placebo; daim tawv nqaij tshem tawm lossis yuav luag tshem tawm hauv 40 mus rau 59% ntawm cov neeg mob noj upadacitinib, piv nrog 11% ntawm cov neeg mob hauv pawg placebo.

Ulcerative colitis
Ob qhov kev tshawb fawb tseem ceeb uas muaj 988 tus neeg mob tau pom tias upadacitinib tau ua haujlwm zoo ntawm kev tshem tawm cov tsos mob thiab txhim kho cov kab mob hauv cov kab mob hauv lub plab ntawm lub plab me me mus rau cov neeg mob uas muaj kab mob uas tsis tau teb rau lwm yam kev kho mob lossis leej twg tsis tuaj yeem zam lwm yam kev kho mob.
Tom qab yim lub lis piam ntawm kev kho mob thaum cov neeg mob tau noj upadacitinib 45 mg lossis placebo ib hnub ib zaug, qhov feem pua ntawm cov neeg mob ntawm upadacitinib uas nws cov tsos mob tau ploj mus lossis yuav luag ploj mus, nrog rau cov mob ib txwm lossis mob me me hauv lub plab hnyuv, yog 26% hauv cov neeg mob. thawj txoj kev tshawb fawb thiab 34% hauv kev tshawb fawb thib ob, piv nrog yuav luag 5% thiab 4% rau cov neeg siv cov placebo.

Crohn tus kab mob
Ob qhov kev tshawb fawb tseem ceeb uas suav nrog tag nrho ntawm 1,021 tus neeg mob uas muaj mob nruab nrab mus rau mob hnyav Crohn tus kab mob tau pom tias upadacitinib tau zoo los txhim kho cov tsos mob ntawm tus kab mob. Tom qab 12 lub lis piam ntawm kev kho mob thaum cov neeg mob noj upadacitinib 45 mg lossis placebo ib hnub ib zaug, qhov feem pua ntawm cov neeg mob ntawm upadacitinib uas nws cov tsos mob tau ploj mus lossis yuav luag ploj mus hauv ob txoj kev tshawb fawb yog 40% thiab 51%, piv nrog 14% thiab 22% rau cov neeg siv cov placebo. Kev mob ntawm lub plab hnyuv tau txo qis ntau dua li ib nrab ntawm 35% thiab 46% ntawm cov neeg mob muab upadacitinib, piv nrog 4% thiab 13% hauv cov neeg mob muab cov placebo.

Peb lub Hoobkas

Zhejiang Fengfu Pharma Co., txwv tsis pub koom nrog hauv kev txhim kho, tsim khoom thiab kev lag luam ntawm cov khoom siv tshuaj, cov khoom xyaw zaub mov, cov vitamins, cov tshuaj nruab nrab thiab tshuaj.
Fengfu Pharma, headquartered nyob rau hauv Hangzhou, Tuam Tshoj, nrog 3 ntau lawm bases nyob rau hauv Shandong, Zhejiang thiab Hebei nyias, uas muaj ntau xyoo ntawm kev paub nyob rau hauv zus tau tej cov APIs, vitamins thiab tshuaj cov khoom. Cov chaw no tau lees paub GMP, ISO, FAMI-QS, KOSHER, HALAL, thiab lwm yam. Peb muaj kev tswj xyuas tag nrho peb cov khoom tsim, tsim, thiab tsim cov txheej txheem, ua tsaug rau peb cov cuab yeej siv siab heev, cov txheej txheem, thiab cov chaw soj ntsuam.
Nrog rau kev muaj peev xwm tseem ceeb hauv kev siv tshuaj thiab zaub mov noj qab haus huv, Fengfu Pharma tau tsim kev lag luam thoob plaws ntiaj teb. Peb muaj Strategic Marketing Partners feem hauv Mumbai thiab Dubai. Peb npaj txhij los muab koj nrog peb cov khoom thiab cov kev pabcuam zoo tshaj plaws.
Peb lub hom phiaj yog los muab koj cov khoom lag luam zoo thiab cov kev pabcuam tshaj lij rau kev sib nrig sib pab. Peb kuj txaus siab ua haujlwm nrog cov neeg koom tes thoob ntiaj teb los tsim kom muaj lub neej yav tom ntej zoo ua ke.

product-1-1

FAQ

Q: Yam tshuaj twg yog upadacitinib CAS 1310726-60-3?

A: Upadacitinib, yog ib hom tshuaj hu ua JAK inhibitor. Cov tshuaj no ua haujlwm los ntawm kev txwv qhov kev txiav txim ntawm Janus kinase enzymes, uas koom nrog hauv qhov mob uas ua rau cov tsos mob ntawm tus mob rheumatoid mob caj dab thiab qee yam mob.

Q: Puas yog upadacitinib CAS 1310726-60-3 tshuaj tiv thaiv kab mob?

A: Upadacitinib, cov tshuaj nquag hauv Rinvoq, yog cov tshuaj tiv thaiv kab mob. Qhov no txhais tau hais tias nws txo qis kev ua haujlwm ntawm lub cev tiv thaiv kab mob. Upadacitinib ua haujlwm los ntawm kev thaiv cov enzymes hu ua Janus kinases.

Q: upadacitinib CAS 1310726-60-3 ua haujlwm li cas?

A: Upadacitinib siv nws cov txheej txheem ntawm kev ua haujlwm los ntawm inhibiting intracellular cytoplasmic enzymes Janus kinases (JAK), ib pawg ntawm plaub tyrosine kinases (JAK1, JAK2, JAK3, thiab TYK2) koom nrog cov txheej txheem ntawm kev tiv thaiv kab mob sib kis (IMIDs).

Q: Puas yog upadacitinib CAS 1310726-60-3 ua rau hnyav nce?

A: Upadacitinib tuaj yeem ua rau hnyav nce rau qee tus neeg. Qhov hnyav nce tau raug tshaj tawm hauv kev sim tshuaj kho mob upadacitinib raws li kev phiv tshwm sim (tshwm sim hauv 1-10% ntawm cov neeg mob).

Q: Lub sijhawm zoo tshaj plaws los noj upadacitinib CAS 1310726-60-3 yog dab tsi?

A: Noj koj cov tshuaj tib lub sijhawm txhua hnub. Nws yuav pab koj nco ntsoov thaum koj coj nws.

Q: Kuv puas tuaj yeem haus cawv thaum noj upadacitinib CAS 1310726-60-3?

A: Tsis muaj ntaub ntawv qhia txog qhov cuam tshuam ntawm kev noj upadacitinib CAS 1310726-60-3 nrog cawv.

Q: Kuv yuav ua li cas yog tias kuv tsis nco qab nqa kuv cov upadacitinib CAS 1310726-60-3?

A: Coj nws sai li sai tau thaum koj nco qab, tsuav nws yog tsawg kawg 10 teev ua ntej koj koob tshuaj ntxiv. Txwv tsis pub, hla cov koob tshuaj uas koj tsis nco qab thiab noj koj cov tshuaj ntxiv thaum koj xav tau.

Q: Yuav ua li cas kom tsis txhob thaum noj upadacitinib CAS 1310726-60-3?

A: Piv txwv ntawm upadacitinib CAS 1310726-60-3 kev sib cuam tshuam muaj xws li cov tshuaj tua kab mob thiab tshuaj tua kab mob, cov tshuaj uas muaj ritonavir, thiab cov tshuaj plawv zoo li verapamil. Nws yog ib qho tseem ceeb kom qhia rau koj tus kws kho mob thiab kws muag tshuaj txog tag nrho cov tshuaj thiab cov tshuaj uas koj noj ua ntej pib upadacitinib CAS 1310726-60-3.

Q: Kuv puas tuaj yeem plam qhov koob tshuaj upadacitinib CAS 1310726-60-3 yog tias kuv cov tsos mob zoo dua?

A: Tsis yog. Tsis txhob tso tseg lossis hla ib koob tshuaj upadacitinib CAS 1310726-60-3 tshwj tsis yog koj tus kws kho mob qhia. upadacitinib CAS 1310726-60-3 yog siv los kho cov mob ntev, tab sis tsis kho lawv tag nrho. Tso tseg lossis cuam tshuam kev kho mob nrog upadacitinib CAS 1310726-60-3 tuaj yeem ua rau koj tus kab mob hnyav dua, yog li nws tseem ceeb heev uas yuav tsum tau noj koj cov tshuaj txawm tias koj zoo dua.

Q: upadacitinib CAS 1310726-60-3 txawv ntawm lwm cov tshuaj uas kuv noj li cas?

A: Upadacitinib CAS 1310726-60-3 pab txo qis qhov mob hauv qab ua rau koj cov tsos mob thiab tej zaum yuav ua haujlwm txawv rau lwm cov tshuaj uas koj yuav noj. Txhua yam tshuaj uas koj tau muab ua lub luag haujlwm tshwj xeeb thiab txhais tau hais tias hauv koj txoj kev noj qab haus huv tag nrho. Txhawm rau kom tau txais txiaj ntsig zoo tshaj plaws los ntawm koj txoj kev npaj kho mob, noj tag nrho koj cov tshuaj raws li tau hais tseg - ib txwm nug yog tias koj tsis paub meej.

Q: Kuv tau siv tshuaj txhaj rau kuv tus mob, vim li cas kuv thiaj li noj ntsiav tshuaj tam sim no?

A: Tej zaum koj yuav tau ua tshuaj rau koj tus mob uas yuav tsum tau txhaj tshuaj. Cov khoom xyaw nquag ntawm upadacitinib CAS 1310726-60-3 yog muab rau hauv daim ntawv ntsiav tshuaj.

Q: Puas yog upadacitinib CAS 1310726-60-3 cuam tshuam koj txoj kev pw tsaug zog?

A: Upadacitinib CAS 1310726-60-3 tuaj yeem ua rau koj tsaug zog lossis nkees. Hauv kev tshawb fawb ntawm cov neeg raug kho rau eczema (atopic dermatitis) nkees tau tshaj tawm tias yog ib qho kev mob tshwm sim. upadacitinib CAS 1310726-60-3 kuj tseem tuaj yeem ua rau koj muaj kev pheej hmoo rau kev kis kab mob lossis cov qe ntshav liab qis uas tuaj yeem ua rau koj tsaug zog.

Q: Dab tsi yog qhov ua tiav ntawm upadacitinib CAS 1310726-60-3?

A: Cov nqi pheej yig yog 87.1% ntawm lub lim tiam 12, 81.7% ntawm lub lim tiam 24 thiab 62.8% ntawm lub lim tiam 52.

Q: Kev nyab xeeb npaum li cas yog upadacitinib CAS 1310726-60-3?

A: Qhov nce ntawm pob txuv tau pom hauv cov neeg mob AD nkaus xwb. Cov lus xaus Kev tshawb pom los ntawm qhov kev tshuaj ntsuam no qhia tau hais tias upadacitinib feem ntau tau txais txiaj ntsig zoo nrog kev pom qhov sib txawv hauv kev nyab xeeb cov ntaub ntawv yuav muaj kev cuam tshuam ntawm cov neeg mob sib txawv ntawm RA, PsA, AS thiab AD cov neeg.

Q: Nws siv sijhawm ntev npaum li cas rau upadacitinib CAS 1310726-60-3 ua haujlwm?

A: Qee tus neeg mob yuav hnov qhov kev txhim kho ntawm cov tsos mob sai li sai tau thaum 1-2 lub lis piam pib upadacitinib. Qee tus neeg mob yuav tsum muab sijhawm rau cov tshuaj pib ua haujlwm. Feem ntau, mus txog 2 lub hlis yuav tsum pom muaj txiaj ntsig.

Q: Pab pawg hnub nyoog twg yog upadacitinib CAS 1310726-60-3 rau?

A: Upadacitinib CAS 1310726-60-3 yog qhia rau kev kho mob ntawm cov neeg laus thiab cov menyuam yaus hnub nyoog 12 xyoos thiab laus dua nrog refractory, nruab nrab mus rau mob atopic dermatitis uas nws tus kab mob tsis raug tswj kom txaus nrog lwm cov khoom siv tshuaj, suav nrog biologics, lossis thaum twg kev siv cov kev kho mob no yog inadvisable.

Q: Upadacitinib CAS 1310726-60-3 muab li cas?

A: Upadacitinib los ua ib ntsiav tshuaj, lossis ntsiav tshuaj, noj los ntawm qhov ncauj. Hauv thawj 3 lub hlis, nws feem ntau tau noj ntawm koob tshuaj 45 mg, ib hnub ib zaug. Thaum cov tshuaj pib ua haujlwm, cov koob tshuaj tuaj yeem txo qis rau 15 mg, ib hnub ib zaug.

Q: Kuv yuav ua li cas yog tias kuv tsis noj tshuaj upadacitinib CAS 1310726-60-3?

A: Noj koj cov tshuaj tsis tau sai li sai tau thaum koj nco qab. Txawm li cas los xij, yog tias nws yuav luag lub sijhawm rau koj qhov koob tshuaj ntxiv (12 teev lossis tsawg dua), hla qhov koob tshuaj uas tsis tau thiab txuas ntxiv nrog koj cov koob tshuaj ntxiv raws li tau teem tseg. Tsis txhob noj 2 koob tshuaj tib lub sijhawm.

Q: Yuav tsum kuaj dab tsi thaum kuv nyob rau upadacitinib CAS 1310726-60-3?

A: Ua ntej pib kho upadacitinib, koj yuav tsum tau kuaj ntshav kuaj seb puas muaj kab mob siab B thiab kab mob ntsws. Tej zaum koj kuj yuav tau kuaj kab mob ntsws txhua xyoo. Kev suav ntshav thiab kuaj lub siab ua tiav txhua 4 lub hlis thaum nyob rau upadacitinib.
Upadacitinib tuaj yeem nce qib roj cholesterol. Yog li, cov cholesterol (lipid) kev kuaj xyuas vaj huam sib luag tau pom zoo ua ntej thiab ntu ntu thaum nyob ntawm upadacitinib.

Q: Puas yog upadacitinib CAS 1310726-60-3 nyab xeeb?

A: Xaus: Feem ntau cov kev tshawb fawb qhia tias upadacitinib tsis muaj qhov sib txawv ntawm qhov kev tshawb fawb txog kev nyab xeeb piv rau cov kev kho mob lossis cov placebo hauv cov neeg mob RA, PsA, AS, AD, UC, thiab CD. Qee qhov kev tshawb fawb tau tshaj tawm cov nqi siab dua, tab sis kev tshawb pom tsis sib haum nrog kev txhais lus tsawg.

Cim npe nrov: upadacitinib cas 1310726-60-3, China upadacitinib cas 1310726-60-3 manufacturers, lwm tus neeg, Hoobkas